×
NexImmune Price to Free Cash Flow Ratio 2020-2024 | NEXI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
NexImmune price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
View More
NexImmune Price to Free Cash Flow Ratio 2020-2024 | NEXI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
NexImmune price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$140.4B
Bristol Myers Squibb (BMY)
$114.2B
Gilead Sciences (GILD)
$113.5B
Vertex Pharmaceuticals (VRTX)
$102.1B
CSL (CSLLY)
$83.7B
Regeneron Pharmaceuticals (REGN)
$77.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$37.8B
Alnylam Pharmaceuticals (ALNY)
$30.8B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$21.5B
Illumina (ILMN)
$21.3B
BeiGene (BGNE)
$17B
Moderna (MRNA)
$15.2B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$12.9B
Insmed (INSM)
$12.4B
BioMarin Pharmaceutical (BMRN)
$12.4B
Sarepta Therapeutics (SRPT)
$11.4B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$10.7B
Exact Sciences (EXAS)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.2B
QIAGEN (QGEN)
$10.1B
Exelixis (EXEL)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B